Effect of COX-2 Inhibitors on Preventing Urethral Stricture Return After Direct Vision Internal Urethrotomy in Adult Men

What this Trial Is About

Researchers are evaluating the use of nonsteroidal anti-inflammatory drugs NSAIDs, specifically a COX-2 inhibitor, to prevent the recurrence of urethral strictures after direct visual internal urethrotomy DVIU. Urethral strictures often result from idiopathic causes or medical procedures and have higher recurrence rates in certain conditions, such as multiple or long strictures and infections. This study aims to assess the safety and effectiveness of NSAIDs in reducing stricture recurrence following surgery. Participants will be randomly assigned to one of two groups. One group will receive DVIU followed by NSAIDs for three weeks, while the other group will receive DVIU followed by a placebo for the same duration. The study uses a single-blind design where participants do not know which treatment they receive. The treatments are given postoperatively to compare their effect on preventing stricture recurrence. During the study, participants will be monitored for urethral stricture recurrence 90 days after surgery. Additional assessments include symptom scores using the International Prostate Symptom Score IPSS, quality of life evaluations, maximum urine flow rate, and any complications occurring within 90 days postoperatively. This follow-up period allows researchers to evaluate treatment impact and safety over three months.

Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?